

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 13373

TABLE A.7.1.—UGDP DATA: RELATIVE ALLOCATION OF TOTAL AND CARDIOVASCULAR DEATHS AND EFFECTIVE SAMPLE SIZE

Treatment received	Assigned treatment				Totals
	Placebo	Tolbutamide	Standard dose insulin	Variable dose insulin	
Treatment as assigned: ¹					
d'	12.9	19.9	6.9	² 6.9	46.6
d''	6.4	17.9	3.9	5.6	33.8
n'	115.6	119.5	65.7	53.9	354.7
Dose modification or other treatment:					
Placebo:					
d'	2.8				2.8
d''	1.0				1.0
n'	48.6				48.6
Tolbutamide:					
d'	0	7.7	0	0	7.7
d''	0	5.7	0	0	5.7
n'	.5	51.4	.8	.6	53.3
Variable dose insulin:					
d'	1.2	.4	12.5	³ 8.5	22.6
d''	1.2	.4	8.6	³ 4.6	14.8
n'	6.9	10.7	111.1	³ 121.9	250.6
None:					
d'	4.1	2.0	.6	2.6	9.3
d''	1.4	2.0	.5	1.8	5.7
n'	33.4	22.4	32.4	27.6	115.8
Totals:					
d'	21.0	30.0	20.0	18.0	89.0
d''	10.0	26.0	13.0	12.0	61.0
n'	205.0	204.0	210.0	204.0	823.0

¹ d' indicates total deaths; d'', deaths from cardiovascular causes; and n', effective sample size.

² These figures are associated with the initially selected dose of insulin.

³ These figures are associated with the subsequently selected dose of insulin.

TABLE A.7.2.—UGDP DATA: DEATH RATES AND FAILURE RATES BY ASSIGNED TREATMENT AND DOSE GIVEN ¹

Dose given	Assigned Treatment			
	Placebo	Tolbutamide	Standard dose insulin	Variable dose insulin ²
Cardiovascular deaths:				
As assigned:				
θ'	0.06	0.15	0.06	0.10
λ'	.9	2.5	1.0	1.8
Dose modified:				
θ'	.02	.11	.08	.04
λ'	.3	1.9	1.2	.6
No drug:				
θ'	.04	.09	.02	.07
λ'	.7	1.1	.3	1.0
Total deaths:				
As assigned:				
θ'	.11	.17	.11	.13
λ'	1.9	2.8	1.8	2.3
Dose modified:				
θ'	.06	.15	.11	.07
λ'	.9	2.5	1.8	1.1
No drug:				
θ'	.12	.09	.02	.09
λ'	2.1	1.1	.25	1.5

¹ Death rate (θ') is effective number of deaths/effective sample size; failure rate (λ') is deaths per hundred patient-years of follow-up.

² Combining both modification groups results in $\theta' = 10.2/175.9 = 0.06$, $\lambda' = 0.9$ for cardiovascular deaths; $\theta' = 15.4/175.9 = 0.09$, $\lambda' = 1.4$ for total deaths.